Search

Your search keyword '"Donnelly, J Peter"' showing total 164 results
Start Over Author "Donnelly, J Peter" Publication Year Range Last 10 years
164 results on '"Donnelly, J Peter"'

1. When to change treatment of acute invasive aspergillosis: an expert viewpoint

Author

Slavin, Monica A, Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A, Cuenca-Estrella, Manuel, Donnelly, J Peter, Groll, Andreas H, Lortholary, Olivier, Marty, Francisco M, Nucci, Marcio, Rex, John H, Rijnders, Bart JA, Thompson, George R, Verweij, Paul E, White, P Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A

Subjects
Infectious Diseases, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Antifungal Agents, Aspergillosis, Bronchoalveolar Lavage Fluid, Humans, Immunocompromised Host, Invasive Fungal Infections, Invasive Pulmonary Aspergillosis, Mannans, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences
Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.

Published
2021

2. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author

Donnelly, J Peter, Chen, Sharon C, Kauffman, Carol A, Steinbach, William J, Baddley, John W, Verweij, Paul E, Clancy, Cornelius J, Wingard, John R, Lockhart, Shawn R, Groll, Andreas H, Sorrell, Tania C, Bassetti, Matteo, Akan, Hamdi, Alexander, Barbara D, Andes, David, Azoulay, Elie, Bialek, Ralf, Bradsher, Robert W, Bretagne, Stephane, Calandra, Thierry, Caliendo, Angela M, Castagnola, Elio, Cruciani, Mario, Cuenca-Estrella, Manuel, Decker, Catherine F, Desai, Sujal R, Fisher, Brian, Harrison, Thomas, Heussel, Claus Peter, Jensen, Henrik E, Kibbler, Christopher C, Kontoyiannis, Dimitrios P, Kullberg, Bart-Jan, Lagrou, Katrien, Lamoth, Frédéric, Lehrnbecher, Thomas, Loeffler, Jurgen, Lortholary, Olivier, Maertens, Johan, Marchetti, Oscar, Marr, Kieren A, Masur, Henry, Meis, Jacques F, Morrisey, C Orla, Nucci, Marcio, Ostrosky-Zeichner, Luis, Pagano, Livio, Patterson, Thomas F, Perfect, John R, Racil, Zdenek, Roilides, Emmanuel, Ruhnke, Marcus, Prokop, Cornelia Schaefer, Shoham, Shmuel, Slavin, Monica A, Stevens, David A, Thompson, George R, Vazquez, Jose A, Viscoli, Claudio, Walsh, Thomas J, Warris, Adilia, Wheat, L Joseph, White, P Lewis, Zaoutis, Theoklis E, and Pappas, Peter G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Prevention, Clinical Research, Good Health and Well Being, Antifungal Agents, Consensus, Humans, Immunocompromised Host, Invasive Fungal Infections, Mycoses, Neoplasms, consensus, definitions, invasive fungal diseases, diagnosis, research, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundInvasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential.MethodsTo achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved.ResultsThere is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses.ConclusionsThese updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

Published
2020

3. Polymerase Chain Reaction on Respiratory Tract Specimens of Immunocompromised Patients to Diagnose Pneumocystis Pneumonia: A Systematic Review and Meta-analysis

Author

Brown, Lottie, primary, Rautemaa-Richardson, Riina, additional, Mengoli, Carlo, additional, Alanio, Alexandre, additional, Barnes, Rosemary A, additional, Bretagne, Stéphane, additional, Chen, Sharon C A, additional, Cordonnier, Catherine, additional, Donnelly, J Peter, additional, Heinz, Werner J, additional, Jones, Brian, additional, Klingspor, Lena, additional, Loeffler, Juergen, additional, Rogers, Thomas R, additional, Rowbotham, Eleanor, additional, White, P Lewis, additional, and Cruciani, Mario, additional

Published
2024
Full Text
View/download PDF

4. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia

Author

Greinix, Hildegard, Maertens, Johan, De Greef, Julien, Slavin, Monica, Spriet, Isabel, Hubacek, Petr, Bergeron, Anne, Cordonnier, Catherine, Kanerva, Jukka, Herbrecht, Raoul, Herrmann, Jean-Louis, Lanternier, Fanny, Bondeelle, Louise, Robin, Christine, Einsele, Hermann, Lehrnbecher, Thomas, Groll, Andreas, Maschmeyer, Georg, Lange, Christoph, von Lilienfeld-Toal, Marie, Pana, Dorothea, Roilides, Emmanuel, Kassa, Csaba, Averbuch, Diana, Engelhard, Dan, Cesaro, Simone, Mikulska, Malgorzata, Pagano, Livio, Castagnola, Elio, Compagno, Francesca, Goletti, Delia, Mesini, Alessio, Donnelly, Peter J, Styczynski, Jan, Botelho de Sousa, Aida, Aljurf, Mahmoud, de la Camara, Rafael, Navarro, David, Rovira, Montserrat, Franquet, Tomas, Garcia-Vidal, Carol, Ljungman, Per, Paukssen, Karlis, Ammann, Roland, Lamoth, Frédéric, Hirsch, Hans, Ritz, Nicole, Akova, Murat, Ceesay, Mansour, Warris, Adilia, Chemaly, Roy, and Donnelly, J Peter

Published
2022
Full Text
View/download PDF

6. An Overview of Systematic Reviews of Polymerase Chain Reaction (PCR) for the Diagnosis of Invasive Aspergillosis in Immunocompromised People: A Report of the Fungal PCR Initiative (FPCRI)—An ISHAM Working Group

Author

Cruciani, Mario, primary, White, P. Lewis, additional, Barnes, Rosemary A., additional, Loeffler, Juergen, additional, Donnelly, J. Peter, additional, Rogers, Thomas R., additional, Heinz, Werner J., additional, Warris, Adilia, additional, Morton, Charles Oliver, additional, Lengerova, Martina, additional, Klingspor, Lena, additional, Sendid, Boualem, additional, and Lockhart, Deborah E. A., additional

Published
2023
Full Text
View/download PDF

8. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer

Author

Maertens, Johan, Lodewyck, Tom, Donnelly, J Peter, Chantepie, Sylvain, Robin, Christine, Blijlevens, Nicole, Turlure, Pascal, Selleslag, Dominik, Baron, Frederic, Aoun, Mickael, Heinz, Werner J, Bertz, Hartmut, Racil, Zdenek, Vandercam, Bernard, Drgona, Lubos, Coiteux, Valerie, Llorente, Cristina Castilla, Schaefer-Prokop, Cornelia, Paesmans, Marianne, Ameye, Lieveke, Meert, Liv, Cheung, Kin Jip, Hepler, Deborah A, Loeffler, Juergen, Barnes, Rosemary, Marchetti, Oscar, Verweij, Paul, Lamoth, Frederic, Bochud, Pierre-Yves, Schwarzinger, Michael, and Cordonnier, Catherine

Subjects
Microbiology (medical), empiric, Science & Technology, Immunology, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], FEBRILE, STEM-CELL TRANSPLANTS, Microbiology, THERAPY, PERSISTENT FEVER, preemptive, CIRCULATING GALACTOMANNAN, All institutes and research themes of the Radboud University Medical Center, Infectious Diseases, galactomannan, neutropenia, COMPUTED-TOMOGRAPHY, INVASIVE FUNGAL-INFECTION, LIPOSOMAL AMPHOTERICIN-B, ASPERGILLOSIS, Life Sciences & Biomedicine, HEMATOLOGY PATIENTS, antifungal, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Background Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown. Methods Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically. The primary end point of this noninferiority study was overall survival (OS) 42 days after randomization. Results Of 556 patients recruited, 549 were eligible: 275 in arm A and 274 in arm B. Eighty percent of the patients had AML or MDS requiring high-dose chemotherapy, and 93% of them were in the first induction phase. At day 42, the OS was not inferior in arm B (96.7%; 95% confidence interval [CI], 93.8%–98.3%) when compared with arm A (93.1%; 95% CI, 89.3%–95.5%). The rates of IFDs at day 84 were not significantly different, 7.7% (95% CI, 4.5%–10.8%) in arm B vs 6.6% (95% CI, 3.6%–9.5%) in arm A. The rate of patients who received caspofungin was significantly lower in arm B (27%) than in arm A (63%; P < .001). Conclusions The preemptive antifungal strategy was safe for high-risk neutropenic patients given fluconazole as prophylaxis, halving the number of patients receiving antifungals without excess mortality or IFDs. Clinical Trials Registration. NCT01288378; EudraCT 2010-020814-27.

Published
2022

10. Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer

Author

Haeusler, Gabrielle M., Bauters, Tiene, Laureys, Geneviève, Spassova, Maria, Klaassen, Robert, Alexander, Sarah, Silva, Pamela, Tordecilla, Juan, Paesmans, Marianne, Donnelly, J. Peter, Simon, Arne, Hann, Ian M., Ranasinghe, Neil, Riley, Richard D., Chisholm, Julia, Yeomanson, Daniel, Sutton, Alex J., Dommett, Rachel, Gupta, Ajay, Castagnola, Elio, Haupt, Ricarrdo, Meidema, Karin, Kuehne, Thomas, Kitanovski, Lidija, Niggli, Felix, Nadal, David, Tezcan, Gulsun, Hakim, Hana, Stryjewski, Glen, Phillips, Robert S., Bhuller, Kaljit, Sung, Lillian, Ammann, Roland A., Tissing, Wim J.E., Lehrnbecher, Thomas, and Stewart, Lesley A.

Published
2016
Full Text
View/download PDF

12. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus

Author

Verweij, Paul E., Ananda-Rajah, Michelle, Andes, David, Arendrup, Maiken C., Brüggemann, Roger J., Chowdhary, Anuradha, Cornely, Oliver A., Denning, David W., Groll, Andreas H., Izumikawa, Koichi, Kullberg, Bart Jan, Lagrou, Katrien, Maertens, Johan, Meis, Jacques F., Newton, Pippa, Page, Iain, Seyedmousavi, Seyedmojtaba, Sheppard, Donald C., Viscoli, Claudio, Warris, Adilia, and Donnelly, J. Peter

Published
2015
Full Text
View/download PDF

13. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia

Author

Bergeron, Anne, primary, Mikulska, Malgorzata, additional, De Greef, Julien, additional, Bondeelle, Louise, additional, Franquet, Tomas, additional, Herrmann, Jean-Louis, additional, Lange, Christoph, additional, Spriet, Isabel, additional, Akova, Murat, additional, Donnelly, J Peter, additional, Maertens, Johan, additional, Maschmeyer, Georg, additional, Rovira, Montserrat, additional, Goletti, Delia, additional, de la Camara, Rafael, additional, Greinix, Hildegard, additional, Slavin, Monica, additional, Hubacek, Petr, additional, Bergeron, Anne, additional, Cordonnier, Catherine, additional, Kanerva, Jukka, additional, Herbrecht, Raoul, additional, Lanternier, Fanny, additional, Robin, Christine, additional, Einsele, Hermann, additional, Lehrnbecher, Thomas, additional, Groll, Andreas, additional, von Lilienfeld-Toal, Marie, additional, Pana, Dorothea, additional, Roilides, Emmanuel, additional, Kassa, Csaba, additional, Averbuch, Diana, additional, Engelhard, Dan, additional, Cesaro, Simone, additional, Pagano, Livio, additional, Castagnola, Elio, additional, Compagno, Francesca, additional, Mesini, Alessio, additional, Donnelly, Peter J, additional, Styczynski, Jan, additional, Botelho de Sousa, Aida, additional, Aljurf, Mahmoud, additional, Navarro, David, additional, Garcia-Vidal, Carol, additional, Ljungman, Per, additional, Paukssen, Karlis, additional, Ammann, Roland, additional, Lamoth, Frédéric, additional, Hirsch, Hans, additional, Ritz, Nicole, additional, Ceesay, Mansour, additional, Warris, Adilia, additional, and Chemaly, Roy, additional

Published
2022
Full Text
View/download PDF

15. Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group

Author

Herbrecht, Raoul, Patterson, Thomas F., Slavin, Monica A., Marchetti, Oscar, Maertens, Johan, Johnson, Elizabeth M., Schlamm, Haran T., Donnelly, J. Peter, and Pappas, Peter G.

Published
2015

16. Correction to: Epidemiology and Outcome of Fungemia in a Cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031)

Author

Cornely, Oliver A, primary, Gachot, Bertrand, additional, Akan, Hamdi, additional, Bassetti, Matteo, additional, Uzun, Omrun, additional, Kibbler, Christopher, additional, Marchetti, Oscar, additional, de Burghgraeve, Peter, additional, Ramadan, Safaa, additional, Pylkkanen, Liisa, additional, Ameye, Lieveke, additional, Paesmans, Marianne, additional, and Donnelly, J Peter, additional

Published
2022
Full Text
View/download PDF

17. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.

Author

Maertens, Johan, Lodewyck, Tom, Donnelly, J Peter, Chantepie, Sylvain, Robin, Christine, Blijlevens, Nicole, Turlure, Pascal, Selleslag, Dominik, Baron, Frédéric, Aoun, Mickael, Heinz, Werner J, Bertz, Hartmut, Ráčil, Zdeněk, Vandercam, Bernard, Drgona, Lubos, Coiteux, Valerie, Llorente, Cristina Castilla, Schaefer-Prokop, Cornelia, Paesmans, Marianne, and Ameye, Lieveke

Subjects
MYELODYSPLASTIC syndromes, ANTIFUNGAL agents, CLINICAL trials, CONFIDENCE intervals, CHEST X rays, CASPOFUNGIN, CANCER chemotherapy, NEUTROPENIA, PATIENTS, MEDICAL screening, RISK assessment, RANDOMIZED controlled trials, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, RESEARCH funding, MYCOSES, FLUCONAZOLE, HEMATOPOIETIC stem cell transplantation, STATISTICAL sampling, COMPUTED tomography, CHEMOPREVENTION, TRANSPLANTATION of organs, tissues, etc., PATIENT safety, DISEASE risk factors
Abstract

Background Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown. Methods Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically. The primary end point of this noninferiority study was overall survival (OS) 42 days after randomization. Results Of 556 patients recruited, 549 were eligible: 275 in arm A and 274 in arm B. Eighty percent of the patients had AML or MDS requiring high-dose chemotherapy, and 93% of them were in the first induction phase. At day 42, the OS was not inferior in arm B (96.7%; 95% confidence interval [CI], 93.8%–98.3%) when compared with arm A (93.1%; 95% CI, 89.3%–95.5%). The rates of IFDs at day 84 were not significantly different, 7.7% (95% CI, 4.5%–10.8%) in arm B vs 6.6% (95% CI, 3.6%–9.5%) in arm A. The rate of patients who received caspofungin was significantly lower in arm B (27%) than in arm A (63%; P <.001). Conclusions The preemptive antifungal strategy was safe for high-risk neutropenic patients given fluconazole as prophylaxis, halving the number of patients receiving antifungals without excess mortality or IFDs. Clinical Trials Registration. NCT01288378; EudraCT 2010-020814-27. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. An overview of using fungal DNA for the diagnosis of invasive mycoses

Author

White, P. Lewis, primary, Alanio, Alexandre, additional, Brown, Lottie, additional, Cruciani, Mario, additional, Hagen, Ferry, additional, Gorton, Rebecca, additional, Lackner, Michaela, additional, Millon, Laurence, additional, Morton, C. Oliver, additional, Rautemaa-Richardson, Riina, additional, Barnes, Rosemary A., additional, Donnelly, J Peter, additional, and Loffler, Juergen, additional

Published
2022
Full Text
View/download PDF

21. Contributors

Author

Aagaard, Kjersti, primary, Abrahamian, Fredrick M., additional, Allos, Ban Mishu, additional, Andes, David R., additional, Aoki, Fred Y., additional, Apicella, Michael A., additional, Ard, Kevin L., additional, Arias, Cesar A., additional, Aronoff, David M., additional, Augenbraun, Michael H., additional, Averhoff, Francisco, additional, Azar, Dimitri T., additional, Baddour, Larry M., additional, Baden, Lindsey R., additional, Baker, Carol J., additional, Ballard, Ronald C., additional, Barber, Gerard R., additional, Barnes, Scott D., additional, Barouch, Dan H., additional, Barrett, Alan D., additional, Barshak, Miriam Baron, additional, Basavaraju, Sridhar V., additional, Batteiger, Byron E., additional, Baum, Stephen G., additional, Bayer, Arnold S., additional, Beckham, J. David, additional, Beekmann, Susan E., additional, Bell, Beth P., additional, Bennett, John E., additional, Bente, Dennis A., additional, Berbari, Elie F., additional, Berman, Jonathan, additional, Bertino, Joseph S., additional, Bhimraj, Adarsh, additional, Birdsall, Holly H., additional, Bisno, Alan L., additional, Blackburn, Brian G., additional, Blanton, Lucas S., additional, Blaser, Martin J., additional, Bleck, Thomas P., additional, Blijlevens, Nicole M.A., additional, Bobak, David A., additional, Bonnez, William, additional, Boothroyd, John C., additional, Borio, Luciana L., additional, Bosque, Patrick J., additional, Bower, John, additional, Bradsher, Robert W., additional, Brook, Itzhak, additional, Brown, Kevin E., additional, Brown, Patricia D., additional, Brown-Elliott, Barbara A., additional, Bruhn, Roberta L., additional, Bryant, Amy E., additional, Burd, Eileen M., additional, Burns, Jane C., additional, Bush, Larry M., additional, Calderwood, Stephen B., additional, Cano, Luz Elena, additional, Carpenter, Charles C.J., additional, Caserta, Mary T., additional, Castagnola, Elio, additional, Chaisson, Richard E., additional, Chambers, Henry F., additional, Chapman, Stephen J., additional, Chappell, James D., additional, Chen, Lea Ann, additional, Chen, Sharon C-A, additional, Chow, Anthony W., additional, Clark, Rebecca A., additional, Cohen, Jeffrey I., additional, Cohen, Myron S., additional, Cohen-Poradosu, Ronit, additional, Cohn, Susan E., additional, Connors, Mark, additional, Corey, Lawrence, additional, Cottrell, Mackenzie L., additional, Cover, Timothy L., additional, Cox, Heather L., additional, Craig, William A., additional, Crossley, Kent B., additional, Crumpacker, Clyde S., additional, Curran, James W., additional, Currie, Bart J., additional, D'Agata, Erika, additional, Damon, Inger K., additional, Darouiche, Rabih O., additional, DeBiasi, Roberta L., additional, Deepe, George S., additional, del Rio, Carlos, additional, Delemos, Andrew S., additional, DeLeo, Frank R., additional, DeMuri, Gregory P., additional, Densen, Peter, additional, Dermody, Terence S., additional, Dewar, Robin, additional, Diaz, James H., additional, Dieffenbach, Carl W., additional, Dienstag, Jules L., additional, Doi, Yohei, additional, Dolin, Raphael, additional, Donnelly, J. Peter, additional, Donnenberg, Michael S., additional, Donowitz, Gerald R., additional, Dormitzer, Philip R., additional, Drake, James M., additional, Dumler, J. Stephen, additional, Dummer, J. Stephen, additional, DuPont, Herbert L., additional, Durack, David T., additional, Durand, Marlene L., additional, Edelstein, Paul H., additional, Edmond, Michael B., additional, Edwards, John E., additional, Edwards, Morven S., additional, Eliopoulos, George M., additional, Ellison, Richard T., additional, Endy, Timothy P., additional, Engleberg, N. Cary, additional, Erdem, Hakan, additional, Ernst, Joel D., additional, Ernst, Peter B., additional, Fairhurst, Rick M., additional, Fairley, Jessica K., additional, Falkow, Stanley, additional, Falsey, Ann R., additional, Fauci, Anthony S., additional, Fekete, Thomas, additional, Fey, Paul D., additional, Fine, Steven M., additional, Fitzgerald, Daniel W., additional, Flores, Anthony R., additional, Forster, Derek, additional, Fowler, Vance G., additional, Freedman, David O., additional, Friedlander, Arthur M., additional, Galgiani, John N., additional, Gallin, John I., additional, Gallo, Robert C., additional, Gandhi, Tejal N., additional, Garrett, Wendy S., additional, Gaydos, Charlotte A., additional, Geisbert, Thomas W., additional, Gelfand, Jeffrey A., additional, Gelone, Steven P., additional, Gerding, Dale N., additional, Gershon, Anne A., additional, Gilsdorf, Janet R., additional, Goldstein, Ellie J.C., additional, Gordin, Fred M., additional, Graman, Paul S., additional, Grayson, M. Lindsay, additional, Greene, Jeffrey Bruce, additional, Griffin, Patricia M., additional, Griffith, David E., additional, Guerrant, Richard L., additional, Gul, H. Cem, additional, Haake, David A., additional, Haas, David W., additional, Haines, Charles, additional, Hall, Caroline Breese, additional, Hallak, Joelle, additional, Halperin, Scott A., additional, Hammerschlag, Margaret R., additional, Haque, Rashidul, additional, Harris, Jason B., additional, Hawkins, Claudia, additional, Hay, Roderick J., additional, Hedberg, Craig W., additional, Henderson, David K., additional, Henderson, Donald A., additional, High, Kevin P., additional, Hill, Adrian V.S., additional, Hill, David R., additional, Hinman, Alan R., additional, Hirsch, Martin S., additional, Hodowanec, Aimee, additional, Hohl, Tobias M., additional, Holland, Steven M., additional, Holzman, Robert S., additional, Hook, Edward W., additional, Hooper, David C., additional, Hooton, Thomas M., additional, Horowitz, Harold W., additional, Horsburgh, C. Robert, additional, Horton, James M., additional, Hospenthal, Duane R., additional, Hsueh, Kevin, additional, Hughes, James M., additional, Hynes, Noreen A., additional, Iovine, Nicole M., additional, Iredell, Jonathan R., additional, Ison, Michael G., additional, Janda, J. Michael, additional, Janoff, Edward N., additional, Johannsen, Eric C., additional, Kashuba, Angela D.M., additional, Kasper, Dennis L., additional, Kaye, Donald, additional, Kaye, Keith S., additional, Kaye, Kenneth M., additional, Kazura, James W., additional, Keystone, Jay S., additional, Khabbaz, Rima, additional, Khan, David A., additional, Khudyakov, Yury, additional, Kim, Rose, additional, King, Charles H., additional, Kirchhoff, Louis V., additional, Klein, Jerome O., additional, Klompas, Michael, additional, Knoll, Bettina M., additional, Knowlton, Kirk U., additional, Koehler, Jane E., additional, Kohlhoff, Stephan A., additional, Könönen, Eija, additional, Kontoyiannis, Dimitrios P., additional, Koralnik, Igor J., additional, Korpe, Poonum S., additional, Koshy, Anita A., additional, Kovacs, Joseph A., additional, Kozarsky, Phyllis, additional, Krieger, John, additional, Kroger, Andrew T., additional, Kuehnert, Matthew J., additional, Kumar, Nalin M., additional, Kuruvilla, Merin Elizabeth, additional, LaRocque, Regina C., additional, Leggett, James E., additional, Legido-Quigley, Helena, additional, Levett, Paul N., additional, Levine, Donald P., additional, Levison, Matthew E., additional, Levitt, Alexandra, additional, Lewis, Russell E., additional, Liles, W. Conrad, additional, Lima, Aldo A.M., additional, Limaye, Ajit P., additional, Lipkin, W. Ian, additional, Litman, Nathan, additional, Lorber, Bennett, additional, Luna, Ruth Ann, additional, MacDougall, Conan, additional, Roy, Rob, additional, Mackowiak, Philip A., additional, Madoff, Lawrence C., additional, Magill, Alan J., additional, Maguire, James H., additional, Maldarelli, Frank, additional, Markoff, Lewis, additional, Marrazzo, Jeanne M., additional, Marrie, Thomas J., additional, Marth, Thomas, additional, Martin, David H., additional, Martin, Gregory J., additional, Marty, Francisco M., additional, Maslow, Melanie Jane, additional, Masur, Henry, additional, Mawle, Alison, additional, Mayer, Kenneth H., additional, McBride, John T., additional, McCarthy, James S., additional, McCormack, William M., additional, McGowan, Catherine C., additional, McIntosh, Kenneth, additional, Mead, Paul S., additional, Mikulska, Malgorzata, additional, Miller, Robert F., additional, Miller, Samuel I., additional, Mitchell, David H., additional, Modlin, John F., additional, Mody, Rajal K., additional, Moellering, Robert C., additional, Moffa, Matthew, additional, Moir, Susan, additional, Montoya, José G., additional, Moore, Thomas A., additional, Moreillon, Philippe, additional, Morris, J. Glenn, additional, Morse, Caryn Gee, additional, Moseley, Robin, additional, Munford, Robert S., additional, Murphy, Edward L., additional, Murphy, Timothy F., additional, Murray, Barbara E., additional, Murray, Clinton K., additional, Murray, Patrick R., additional, Musher, Daniel M., additional, Nagel, Jerod L., additional, Nannini, Esteban C., additional, Narezkina, Anna, additional, Nash, Theodore E., additional, Nauseef, William M., additional, Nayak, Jennifer L., additional, Neill, Marguerite A., additional, O'Donnell, Judith A., additional, Ohl, Christopher A., additional, Okhuysen, Pablo C., additional, Onderdonk, Andrew B., additional, Opal, Steven M., additional, Orenstein, Walter A., additional, Osmon, Douglas R., additional, Osterholm, Michael T., additional, Ostroff, Stephen M., additional, Oxman, Michael N., additional, Paessler, Slobodan, additional, Page, Andrea V., additional, Pai, Manjunath P., additional, Palmore, Tara N., additional, Palraj, Raj, additional, Pappas, Peter G., additional, Pasternack, Mark S., additional, Patterson, Thomas F., additional, Pavan-Langston, Deborah, additional, Pegues, David A., additional, Penn, Robert L., additional, Perfect, John R., additional, Perlman, Stanley, additional, Petersen, Brett W., additional, Peterson, Phillip K., additional, Petri, William A., additional, Petti, Cathy A., additional, Philips, Jennifer A., additional, Philley, Julie V., additional, Phillips, Michael, additional, Pickering, Larry K., additional, Piot, Peter, additional, Pogue, Jason M., additional, Pop-Vicas, Aurora, additional, Portal-Celhay, Cynthia, additional, Powers, John H., additional, Price, Richard N., additional, Que, Yok-Ai, additional, Radolf, Justin D., additional, Ram, Sanjay, additional, Raoult, Didier, additional, Ravdin, Jonathan I., additional, Ray, Stuart C., additional, Reboli, Annette C., additional, Reitz, Marvin S., additional, Relman, David A., additional, Renault, Cybèle A., additional, Restrepo, Angela, additional, Rex, John H., additional, Rhee, Elizabeth G., additional, Roberts, Norbert J., additional, Romero, José R., additional, Rothman, Alan L., additional, Roy, Craig R., additional, Ruoff, Kathryn L., additional, Rupp, Mark E., additional, Rupprecht, Charles E., additional, Russo, Thomas A., additional, Rutala, William A., additional, Ryan, Edward T., additional, Safdar, Amar, additional, Sajadi, Mohammad M., additional, Salazar, Juan C., additional, Sarria, Juan Carlos, additional, Savoia, Maria C., additional, Sax, Paul E., additional, Scheld, W. Michael, additional, Schiffer, Joshua T., additional, Schlossberg, David, additional, Schneider, Thomas, additional, Schuchat, Anne, additional, Schwebke, Jane R., additional, Sears, Cynthia L., additional, Segal, Leopoldo N., additional, Sendi, Parham, additional, Sepkowitz, Kent A., additional, Septimus, Edward J., additional, Seregin, Alexey, additional, Shulman, Stanford T., additional, Siberry, George K., additional, Siddiqi, Omar K., additional, Sifri, Costi D., additional, Simberkoff, Michael S., additional, Simonetti, Francesco R., additional, Singh, Kamaljit, additional, Singh, Nina, additional, Singh, Upinder, additional, Sinner, Scott W., additional, Sivapalasingam, Sumathi, additional, Slater, Leonard N., additional, Smulian, A. George, additional, Sobel, Jack D., additional, Sohail, M. Rizwan, additional, Soper, David E., additional, Sorrell, Tania C., additional, Steckelberg, James M., additional, Steere, Allen C., additional, Steigbigel, Neal H., additional, Steinberg, James P., additional, Stephens, David S., additional, Sterling, Timothy R., additional, Stevens, David A., additional, Stevens, Dennis L., additional, Strahilevitz, Jacob, additional, Stratton, Charles W., additional, Suffredini, Anthony F., additional, Suh, Kathryn N., additional, Sulkowski, Mark S., additional, Swartz, Morton N., additional, Talbot, Thomas R., additional, Tan, C. Sabrina, additional, Tan, Ming, additional, Thio, Chloe Lynne, additional, Thomas, David L., additional, Thomas, Lora D., additional, Thomas, Stephen J., additional, Thorner, Anna R., additional, María Tobón, Angela, additional, Tramont, Edmund C., additional, Treanor, John J., additional, Trubiano, Jason, additional, Tsibris, Athe M.N., additional, Tunkel, Allan R., additional, Turner, Ronald B., additional, Tyler, Kenneth L., additional, Uluer, Ahmet, additional, van de Beek, Diederik, additional, van der Velden, Walter J.F.M., additional, Vannier, Edouard G., additional, Van, Trevor C., additional, Versalovic, James, additional, Viscoli, Claudio, additional, Wald, Ellen R., additional, Waldor, Matthew K., additional, Walker, David H., additional, Wallace, Richard J., additional, Walsh, Edward E., additional, Walsh, Stephen R., additional, Walzer, Peter D., additional, Wanke, Christine A., additional, Warren, Cirle A., additional, Washburn, Ronald G., additional, Waters, Valerie, additional, Weber, David J., additional, Weiden, Michael D., additional, Weinberg, Geoffrey A., additional, Weisdorf, Daniel J., additional, Weiss, Louis M., additional, Welch, David F., additional, Wellems, Thomas E., additional, Wenzel, Richard P., additional, Wharton, Melinda, additional, White, A. Clinton, additional, Whitley, Richard J., additional, Wilson, Walter R., additional, Wortmann, Glenn W., additional, Wright, William F., additional, Young, Jo-Anne H., additional, Young, Vincent B., additional, Yun, Nadezhda, additional, Zimmerli, Werner, additional, Zinner, Stephen H., additional, and Zurlo, John J., additional

Published
2015
Full Text
View/download PDF

22. Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity Reply

Author

Wingard, John R, Maertens, Johan, Pagano, Livio, Chen, Sharon C-A, Pappas, Peter G, and Donnelly, J Peter

Subjects
Science & Technology, Infectious Diseases, Immunology, TYROSINE KINASE, Life Sciences & Biomedicine, Microbiology, THERAPY
Abstract

ispartof: CLINICAL INFECTIOUS DISEASES vol:71 issue:12 pages:3266-3266 ispartof: location:United States status: published

Published
2020

25. The Fungal PCR Initiative’s evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: towards a standard for a diagnostics assay

Author

Gits-Muselli, Maud, White, P. Lewis, Mengoli, Carlo, Chen, Sharon, Crowley, Brendan, Dingemans, Gijs, Fréalle, Emilie, Gorton, Rebecca, Guiver, Malcom, Hagen, Ferry, Halliday, Catriona, Johnson, Gemma, Lagrou, Katrien, Lengerova, Martina, Melchers, Willem Jg, Novak-Frazer, Lily, Rautemaa-Richardson, Riina, Scherer, Emeline, Steinmann, Joerg, Cruciani, Mario, Barnes, Rosemary, Donnelly, J. Peter, Loeffler, Juergen, Bretagne, Stéphane, Alanio, Alexandre, Mycologie moléculaire - Molecular Mycology, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), International University of Health and Welfare Hospital (IUHW Hospital), Universita degli Studi di Padova, The University of Sydney, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Manchester University NHS Foundation Trust (MFT), University Medical Center [Utrecht], University Hospitals Leuven [Leuven], Mendel University in Brno (MENDELU), Radboud University Medical Center [Nijmegen], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), University of Duisburg-Essen, Ospedale Fracastoro San Bonifacio [Verona], Cardiff University, Radboud university [Nijmegen], Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), We would like to thank Aude Sturny-Leclère, Marion Benazra, and Dirk Schmid for technical assistance and Dr Samia Hamane for her aid in managing the routine diagnosis of PCP. We also thank Pr Anne Bergeron who is in charge of the broncho-alveolar lavage procedure at Saint-Louis hospital, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Università degli Studi di Padova = University of Padua (Unipd), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Universität Duisburg-Essen = University of Duisburg-Essen [Essen], Radboud University [Nijmegen], and Julius-Maximilians-Universität Würzburg (JMU)

Subjects
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.BID.SPT]Life Sciences [q-bio]/Biodiversity/Systematics, Phylogenetics and taxonomy, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology
Abstract

Quantitative real-time PCR (qPCR) is increasingly used to detect Pneumocystis jirovecii for the diagnosis of Pneumocystis pneumonia (PCP), but there are differences in the nucleic acids targeted, DNA only versus whole nucleic acid (WNA), and also the target genes for amplification. Through the Fungal qPCR Initiative, a working group of the International Society for Human and Animal Mycology, a multicentre and monocentre evaluation of PCP qPCR assays was performed. For the multicentre study, 16 reference laboratories from eight different countries, performing 20 assays analysed a panel consisting of two negative and three PCP positive samples. Aliquots were prepared by pooling residual material from 20 negative or positive- P. jirovecii bronchoalveolar lavage fluids (BALFs). The positive pool was diluted to obtain three concentrations (pure 1:1; 1:100; and 1:1000 to mimic high, medium, and low fungal loads respectively). The monocentre study compared five in-house and five commercial qPCR assays testing 19 individual BALFs on the same amplification platform. Across both evaluations and for all fungal loads, targeting WNA and the mitochondrial small sub-unit (mtSSU) provided the earliest Cq values, compared to only targeting DNA and the mitochondrial large subunit, the major surface glycoprotein or the beta-tubulin genes. Thus, Reverse Transcriptase-qPCR targeting the mtSSU gene could serve as a basis for standardizing the P. jirovecii load, which is essential if qPCR is to be incorporated into clinical care pathways as the reference method, accepting that additional parameters such as amplification platforms still need evaluation

Published
2019

26. When to change treatment of acute invasive aspergillosis: an expert viewpoint.

Author

Slavin, Monica A, Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A, Cuenca-Estrella, Manuel, Donnelly, J Peter, Groll, Andreas H, Lortholary, Olivier, Marty, Francisco M, Nucci, Marcio, Rex, John H, Rijnders, Bart J A, Thompson, George R, Verweij, Paul E, White, P Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A

Subjects
ASPERGILLOSIS, IMMUNOSUPPRESSIVE agents, BRONCHOALVEOLAR lavage, CLINICAL deterioration, COMPUTED tomography, IMMUNITY, ASPERGILLOSIS diagnosis, POLYSACCHARIDES, ANTIFUNGAL agents, RESEARCH, BODY fluids, IMMUNOCOMPROMISED patients, EVALUATION research, PULMONARY aspergillosis, COMPARATIVE studies, RESEARCH funding
Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. Reply to Luppi et al

Author

Wingard, John R, primary, Maertens, Johan, additional, Pagano, Livio, additional, Chen, Sharon C-A, additional, Pappas, Peter G, additional, and Donnelly, J Peter, additional

Published
2020
Full Text
View/download PDF

28. Reply to Herbrecht et al

Author

Baddley, John W, primary, Morrissey, C Orla, additional, Shaefer-Prokop, Cornelia, additional, Chen, Sharon C-A, additional, Pappas, Peter G, additional, and Donnelly, J Peter, additional

Published
2020
Full Text
View/download PDF

30. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author

Donnelly, J Peter, primary, Chen, Sharon C, additional, Kauffman, Carol A, additional, Steinbach, William J, additional, Baddley, John W, additional, Verweij, Paul E, additional, Clancy, Cornelius J, additional, Wingard, John R, additional, Lockhart, Shawn R, additional, Groll, Andreas H, additional, Sorrell, Tania C, additional, Bassetti, Matteo, additional, Akan, Hamdi, additional, Alexander, Barbara D, additional, Andes, David, additional, Azoulay, Elie, additional, Bialek, Ralf, additional, Bradsher, Robert W, additional, Bretagne, Stephane, additional, Calandra, Thierry, additional, Caliendo, Angela M, additional, Castagnola, Elio, additional, Cruciani, Mario, additional, Cuenca-Estrella, Manuel, additional, Decker, Catherine F, additional, Desai, Sujal R, additional, Fisher, Brian, additional, Harrison, Thomas, additional, Heussel, Claus Peter, additional, Jensen, Henrik E, additional, Kibbler, Christopher C, additional, Kontoyiannis, Dimitrios P, additional, Kullberg, Bart-Jan, additional, Lagrou, Katrien, additional, Lamoth, Frédéric, additional, Lehrnbecher, Thomas, additional, Loeffler, Jurgen, additional, Lortholary, Olivier, additional, Maertens, Johan, additional, Marchetti, Oscar, additional, Marr, Kieren A, additional, Masur, Henry, additional, Meis, Jacques F, additional, Morrisey, C Orla, additional, Nucci, Marcio, additional, Ostrosky-Zeichner, Luis, additional, Pagano, Livio, additional, Patterson, Thomas F, additional, Perfect, John R, additional, Racil, Zdenek, additional, Roilides, Emmanuel, additional, Ruhnke, Marcus, additional, Prokop, Cornelia Schaefer, additional, Shoham, Shmuel, additional, Slavin, Monica A, additional, Stevens, David A, additional, Thompson, George R, additional, Vazquez, Jose A, additional, Viscoli, Claudio, additional, Walsh, Thomas J, additional, Warris, Adilia, additional, Wheat, L Joseph, additional, White, P Lewis, additional, Zaoutis, Theoklis E, additional, and Pappas, Peter G, additional

Published
2019
Full Text
View/download PDF

31. The Fungal PCR Initiative's evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: Toward a standard for a diagnostics assay

Author

Gits-Muselli, Maud, primary, White, P Lewis, additional, Mengoli, Carlo, additional, Chen, Sharon, additional, Crowley, Brendan, additional, Dingemans, Gijs, additional, Fréalle, Emilie, additional, L Gorton, Rebecca, additional, Guiver, Malcom, additional, Hagen, Ferry, additional, Halliday, Catriona, additional, Johnson, Gemma, additional, Lagrou, Katrien, additional, Lengerova, Martina, additional, Melchers, Willem J G, additional, Novak-Frazer, Lily, additional, Rautemaa-Richardson, Riina, additional, Scherer, Emeline, additional, Steinmann, Joerg, additional, Cruciani, Mario, additional, Barnes, Rosemary, additional, Donnelly, J Peter, additional, Loeffler, Juergen, additional, Bretagne, Stéphane, additional, and Alanio, Alexandre, additional

Published
2019
Full Text
View/download PDF

34. still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response

Author

Cordonnier, Catherine, Alanio, Alexandre, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J.G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stephane, Maertens, Johan, Agrawal, Samir, Akova, Murat, Aljurf, Mahmoud, Averbuch, Dina, Berg, Thomas, Blennow, Ola, Bruggemann, Roger, Calandra, Thierry, Castagnola, Elio, Cornely, Oliver, De La Camara, Rafael, Drgona, Lubos, Duarte, Rafael, Engelhard, Dan, Girmenia, Corrado, Hargreaves, Ruth, Herbrecht, Raoul, Hirsch, Hans, Hubacek, Petr, Kibbler, Christopher, Klyasova, Galina, Kouba, Michal, Kullberg, Bart Jan, Ljungman, Per, Mallet, Vincent, Marchetti, Oscar, Mikulska, Malgorzata, Munoz, Patricia, Orasch, Christina, Pagano, Livio, Pagliuca, Antonio, Penack, Olaf, Pettrikos, George, Racil, Zdenek, Ribaud, Patricia, Rizzi-Puechal, Valerie, Roilides, Emmanuel, on behalf of the Fifth European Conference on Infections in Leukemia (ECIL-5), The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN), Instituto de Higiene e Medicina Tropical (IHMT), Global Health and Tropical Medicine (GHTM), and TB, HIV and opportunistic diseases and pathogens (THOP)

Subjects
Carinii-pneumonia, Aids, Infectious Diseases, ECIL guidelines, SDG 3 - Good Health and Well-being, Outbreaks, Infection, Infants, Management
Abstract

Made available in DSpace on 2021-09-24T00:56:32Z (GMT). No. of bitstreams: 0 Previous issue date: 2017-04-01 publishersversion published

Published
2017

35. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response

Author

Cordonnier, Catherine, Alanio, Alexandre, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stéphane, Maertens, Johan, Agrawal, Samir, Akova, Murat, Aljurf, Mahmoud, Averbuch, Dina, Berg, Thomas, Blennow, Ola, Brüggemann, Roger, Calandra, Thierry, Castagnola, Elio, Cornely, Oliver, De La Camara, Rafael, Drgona, Lubos, Duarte, Rafael, Engelhard, Dan, Girmenia, Corrado, Hargreaves, Ruth, Herbrecht, Raoul, Hirsch, Hans, Hubacek, Petr, Kibbler, Christopher, Klyasova, Galina, Kouba, Michal, Kullberg, Bart-Jan, Ljungman, Per, Mallet, Vincent, Marchetti, Oscar, Mikulska, Malgorzata, Munoz, Patricia, Orasch, Christina, Pagano, Livio, Pagliuca, Antonio, Penack, Olaf, Pettrikos, George, Racil, Zdenek, Ribaud, Patricia, Rizzi-Puechal, Valérie, Roilides, Emmanuel, Sinko, Janos, Skiada, Anna, Slavin, Monica, Styczynski, Jan, Tissot, Frederic, Tweddle, Lorraine, van Boemmel, Florian, von Lilienfeld-Toal, Marie, Viscoli, Claudio, Ward, Katherine, and Wood, Craig

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, 030106 microbiology, HIV Infections, Pneumocystis carinii, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Hematologic Neoplasms, Humans, Pneumonia, Pneumocystis, Stem Cell Transplantation, Pharmacology, Pharmacology (medical), Infectious Diseases, Medicine, In patient, Intensive care medicine, hematopoietic stem cell transplant, business.industry, Pneumocystis, PNEUMOCYSTIS JIROVECI, Pneumocystis jiroveci, infection, hematopoietic stem cell transplant, Pneumocystis jirovecii Pneumonia, Pneumocystis jiroveci, Pneumonia, medicine.disease, infection, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Stem cell, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

Contains fulltext : 169784.pdf (Publisher’s version ) (Closed access)

Published
2017

38. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Author

Maertens, Johan, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stã©phane, Cordonnier, Catherine, Agrawal, Samir, Kibbler, Christopher, Pagliuca, SIMONE ANTONIO, Ward, Katherine, Akova, Murat, Herbrecht, Raoul, Mallet, Vincent, Ribaud, Patricia, Aljurf, Mahmoud, Averbuch, Dina, Engelhard, Dan, Berg, Thomas, Cornely, Oliver, Penack, Olaf, van Boemmel, Florian, von Lilienfeld-Toal, Marie, Blennow, Ola, Ljungman, Per, Bruggemann, Roger, Donnelly, Peter, Kullberg, Bart-Jan, Melchers, Willem, Calandra, Thierry, Hirsch, Hans, Marchetti, Oscar, Orasch, Christina, Tissot, Frederic, Castagnola, Elio, Girmenia, Corrado, Mikulska, Malgorzata, Pagano, Livio, Viscoli, Claudio, De La Camara, Rafael, Duarte, Rafael, Munoz, Patricia, Drgona, Lubos, Hargreaves, Ruth, Hubacek, Petr, Kouba, Michal, Racil, Zdenek, Klyasova, Galina, Pettrikos, George, Roilides, Emmanuel, Skiada, Anna, Rizzi-Puechal, Valã©rie, Sinko, Janos, Slavin, Monica, Styczynski, Jan, Tweddle, Lorraine, Wood, Craig, Department of Hematology, University Hospital Gasthuisberg, G.B. Rossi Hospital, Verona University, Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Radboud university [Nijmegen], Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Lausanne University Hospital, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire (CNRMA), Institut Pasteur [Paris], Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), The ECIL-5 meeting was supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck, and Pfizer., University Hospital Gasthuisberg [Leuven], Università degli studi di Verona = University of Verona (UNIVR), Radboud University [Nijmegen], Julius-Maximilians-Universität Würzburg (JMU), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Institut Pasteur [Paris] (IP)

Subjects
0301 basic medicine, Microbiology (medical), Antifungal Agents, [SDV]Life Sciences [q-bio], 030106 microbiology, Pneumocitis jirovecii, Chemoprevention, Trimethoprim, Immunocompromised Host, 03 medical and health sciences, 0302 clinical medicine, Trimethoprim, Sulfamethoxazole Drug Combination, Humans, Pharmacology (medical), Pharmacology, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], Sulfamethoxazole Drug Combination, Pneumocystis, Hematologic Neoplasms, Pneumonia, Pneumocystis, Stem Cell Transplantation, Transplant Recipients, Infectious Diseases, immunocomrpomised host, pneumonia, Pneumocitis jirovecii, Pneumonia, 3. Good health, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], 030220 oncology & carcinogenesis, immunocomrpomised host, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Contains fulltext : 172373.pdf (Publisher’s version ) (Closed access) The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and children ( A-I: ) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen ( B-II: ). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.

Published
2016

39. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Author

Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg Larsen, Jannik, Matos, Olga, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Cordonnier, Catherine, Maertens, Johan, Bretagne, Stã©phane, Agrawal, Samir, Kibbler, Christopher, Pagliuca, Antonio, Ward, Katherine, Akova, Murat, Herbrecht, Raoul, Mallet, Vincent, Ribaud, Patricia, Aljurf, Mahmoud, Averbuch, Dina, Engelhard, Dan, Berg, Thomas, Cornely, Oliver, Penack, Olaf, van Boemmel, Florian, von Lilienfeld Toal, Marie, Blennow, Ola, Ljungman, Per, Bruggemann, Roger, Donnelly, Peter, Kullberg, Bart Jan, Melchers, Willem, Calandra, Thierry, Hirsch, Hans, Marchetti, Oscar, Orasch, Christina, Tissot, Frederic, Castagnola, Elio, Girmenia, Corrado, Mikulska, MALGORZATA KAROLINA, Pagano, Livio, Viscoli, Claudio, De La Camara, Rafael, Duarte, Rafael, Munoz, Patricia, Drgona, Lubos, Hargreaves, Ruth, Hubacek, Petr, Kouba, Michal, Racil, Zdenek, Klyasova, Galina, Pettrikos, George, Roilides, Emmanuel, Skiada, Anna, Rizzi Puechal, Valã©rie, Sinko, Janos, Slavin, Monica, Styczynski, Jan, Tweddle, Lorraine, Wood, Craig, Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire (CNRMA), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Université de Lausanne = University of Lausanne (UNIL), Université Catholique de Louvain = Catholic University of Louvain (UCL), Radboud University [Nijmegen], Rigshospitalet [Copenhagen], Copenhagen University Hospital, Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Università degli studi di Verona = University of Verona (UNIVR), Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Julius Maximilians University Wurzburg, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Department of Hematology, University Hospital Gasthuisberg [Leuven], The ECIL-5 meeting was supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck, and Pfizer, Université de Lausanne (UNIL), Radboud university [Nijmegen], G.B. Rossi Hospital, Verona University, University Hospital Gasthuisberg, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Julius-Maximilians-Universität Würzburg (JMU)

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, [SDV]Life Sciences [q-bio], 030106 microbiology, Dapsone, Pneumocystis carinii, 03 medical and health sciences, Immunocompromised Host, 0302 clinical medicine, Diagnostic Tests, Internal medicine, medicine, Pneumocistis jirovecii, Humans, Routine, Pharmacology (medical), 030212 general & internal medicine, Intensive care medicine, Pharmacology, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], business.industry, Diagnostic Tests, Routine, Pneumocystis, Pneumonia, Pneumocystis, Pneumonia, medicine.disease, Trimethoprim, Transplant Recipients, 3. Good health, Fludarabine, Regimen, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Infectious Diseases, Hematologic Neoplasms, Alemtuzumab, Rituximab, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Pentamidine, medicine.drug, immunocompromised host, pneumonia, Pneumocistis jirovecii, Stem Cell Transplantation
Abstract

Item does not contain fulltext The Fifth European Conference on Infections in Leukaemia (ECIL-5) convened a meeting to establish evidence-based recommendations for using tests to diagnose Pneumocystis jirovecii pneumonia (PCP) in adult patients with haematological malignancies. Immunofluorescence assays are recommended as the most sensitive microscopic method (recommendation A-II: ). Real-time PCR is recommended for the routine diagnosis of PCP ( A-II: ). Bronchoalveolar lavage (BAL) fluid is recommended as the best specimen as it yields good negative predictive value ( A-II: ). Non-invasive specimens can be suitable alternatives ( B-II: ), acknowledging that PCP cannot be ruled out in case of a negative PCR result ( A-II: ). Detecting beta-d-glucan in serum can contribute to the diagnosis but not the follow-up of PCP ( A-II: ). A negative serum beta-d-glucan result can exclude PCP in a patient at risk ( A-II: ), whereas a positive test result may indicate other fungal infections. Genotyping using multilocus sequence markers can be used to investigate suspected outbreaks ( A-II: ). The routine detection of dihydropteroate synthase mutations in cases of treatment failure is not recommended ( B-II: ) since these mutations do not affect response to high-dose co-trimoxazole. The clinical utility of these diagnostic tests for the early management of PCP should be further assessed in prospective, randomized interventional studies.

Published
2016

40. Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model

Author

White, P. Lewis, Wiederhold, Nathan P., Loeffler, Juergen, Najvar, Laura K., Melchers, Willem, Herrera, Monica, Bretagne, Stephane, Wickes, Brian, Kirkpatrick, William R., Barnes, Rosemary Ann, Donnelly, J. Peter, Patterson, Thomas F., and Warnock, D. W.

Subjects
Male, 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Time Factors, beta-Glucans, Guinea Pigs, 030106 microbiology, Mycology, Aspergillosis, Polymerase Chain Reaction, Sensitivity and Specificity, Mannans, 03 medical and health sciences, Galactomannan, chemistry.chemical_compound, Blood serum, In vivo, Internal medicine, Animals, Medicine, ddc:610, Stage (cooking), Whole blood, Invasive Pulmonary Aspergillosis, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], Diagnostic Tests, Routine, business.industry, Area under the curve, Galactose, medicine.disease, Clinical trial, Disease Models, Animal, Blood, Molecular Diagnostic Techniques, chemistry, Immunology, Proteoglycans, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

The European Aspergillus PCR Initiative (EAPCRI) has provided recommendations for the PCR testing of whole blood (WB) and serum/plasma. It is important to test these recommended protocols on nonsimulated “ in vivo ” specimens before full clinical evaluation. The testing of an animal model of invasive aspergillosis (IA) overcomes the low incidence of disease and provides experimental design and control that is not possible in the clinical setting. Inadequate performance of the recommended protocols at this stage would require reassessment of methods before clinical trials are performed and utility assessed. The manuscript describes the performance of EAPCRI protocols in an animal model of invasive aspergillosis. Blood samples taken from a guinea pig model of IA were used for WB and serum PCR. Galactomannan and β- d -glucan detection were evaluated, with particular focus on the timing of positivity and on the interpretation of combination testing. The overall sensitivities for WB PCR, serum PCR, galactomannan, and β- d -glucan were 73%, 65%, 68%, and 46%, respectively. The corresponding specificities were 92%, 79%, 80%, and 100%, respectively. PCR provided the earliest indicator of IA, and increasing galactomannan and β- d -glucan values were indicators of disease progression. The combination of WB PCR with galactomannan and β- d -glucan proved optimal (area under the curve [AUC], 0.95), and IA was confidently diagnosed or excluded. The EAPRCI-recommended PCR protocols provide performance comparable to commercial antigen tests, and clinical trials are warranted. By combining multiple tests, IA can be excluded or confirmed, highlighting the need for a combined diagnostic strategy. However, this approach must be balanced against the practicality and cost of using multiple tests.

Published
2016

43. Issues in antifungal stewardship: an opportunity that should not be lost: Table 1

Author

Wattal, Chand, primary, Chakrabarti, Arunaloke, additional, Oberoi, Jaswinder Kaur, additional, Donnelly, J. Peter, additional, Barnes, Rosemary A., additional, Sherwal, B. L., additional, Goel, Neeraj, additional, Saxena, Sonal, additional, Varghese, George M., additional, Soman, Rajeev, additional, Loomba, Poonam, additional, Tarai, Bansidhar, additional, Singhal, Sanjay, additional, Mehta, Naimish, additional, Ramasubramanian, V., additional, Choudhary, Dharma, additional, Mehta, Yatin, additional, Ghosh, Supradip, additional, Muralidhar, Sumathi, additional, and Kaur, Ravinder, additional

Published
2016
Full Text
View/download PDF

44. Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer

Author

Phillips, Robert S., primary, Bhuller, Kaljit, additional, Sung, Lillian, additional, Ammann, Roland A., additional, Tissing, Wim J.E., additional, Lehrnbecher, Thomas, additional, Stewart, Lesley A., additional, Haeusler, Gabrielle M., additional, Bauters, Tiene, additional, Laureys, Geneviève, additional, Spassova, Maria, additional, Klaassen, Robert, additional, Alexander, Sarah, additional, Silva, Pamela, additional, Tordecilla, Juan, additional, Paesmans, Marianne, additional, Donnelly, J. Peter, additional, Simon, Arne, additional, Hann, Ian M., additional, Ranasinghe, Neil, additional, Riley, Richard D., additional, Chisholm, Julia, additional, Yeomanson, Daniel, additional, Sutton, Alex J., additional, Dommett, Rachel, additional, Gupta, Ajay, additional, Castagnola, Elio, additional, Haupt, Ricarrdo, additional, Meidema, Karin, additional, Kuehne, Thomas, additional, Kitanovski, Lidija, additional, Niggli, Felix, additional, Nadal, David, additional, Tezcan, Gulsun, additional, Hakim, Hana, additional, and Stryjewski, Glen, additional

Published
2016
Full Text
View/download PDF

47. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients

Author

Cordonnier, Catherine, primary, Cesaro, Simone, additional, Maschmeyer, Georg, additional, Einsele, Hermann, additional, Donnelly, J. Peter, additional, Alanio, Alexandre, additional, Hauser, Philippe M., additional, Lagrou, Katrien, additional, Melchers, Willem J. G., additional, Helweg-Larsen, Jannik, additional, Matos, Olga, additional, Bretagne, Stéphane, additional, and Maertens, Johan, additional

Published
2016
Full Text
View/download PDF

50. Analytical Comparison of In Vitro -Spiked Human Serum and Plasma for PCR-Based Detection of Aspergillus fumigatus DNA: a Study by the European Aspergillus PCR Initiative

Author

Loeffler, Juergen, primary, Mengoli, Carlo, additional, Springer, Jan, additional, Bretagne, Stéphane, additional, Cuenca-Estrella, Manuel, additional, Klingspor, Lena, additional, Lagrou, Katrien, additional, Melchers, Willem J. G., additional, Morton, C. Oliver, additional, Barnes, Rosemary A., additional, Donnelly, J. Peter, additional, and White, P. Lewis, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results